The Ensign Group, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ENSG research report →
Range $210 – $240
Price Chart
About the company
The Ensign Group, Inc. operates as a healthcare provider, primarily concentrating on post-acute care services, alongside other supporting business ventures. The company's activities are organized into two main divisions: Skilled Services and Real Estate.
- CEO
- Barry R. Port
- IPO
- 2007
- Employees
- 46,000
- HQ
- San Juan Capistrano, CA, US
AI snapshot
Six angles, distilled from the data.
ENSG remains in a long-term uptrend, but it is no longer extended; the stock sits just above its 200-day moving average after pulling back from the 52-week high. That keeps the regime constructive, with the 50-day trend still above the 200-day and the broader setup favoring consolidation rather than breakdown.
Street sentiment stays constructive, with a Buy consensus and an average target of 223.25 versus the current price near the low end of the recent target band. Recent changes were mostly target raises rather than rating downgrades, signaling continued confidence even after the stock’s strong run.
The earnings profile is still favorable: ENSG has beaten EPS in 7 of the last 8 quarters, including a 2.3% beat in the most recent report. Next-year EPS is modeled at 8.7709, up from 6.72 TTM, so shareholders should watch whether operating leverage keeps pace with that step-up.
The pattern leans to net selling, but most recent activity is non-discretionary award and in-kind flow rather than open-market conviction. The only clear sale was a 100-share disposition by director Mark Vincent Parkinson; the rest was dominated by awards and F-InKind transactions.
Profitability is solid for a healthcare operator, with a 17.1% gross margin, 8.85% operating margin, and 7.03% net margin. Growth is still healthy too, with revenue up 14.5% year over year and earnings up 23.9%, while free cash flow reached $757.8 million in 2025.
ENSG stands out for steadier profitability and cash generation than many post-acute peers, supported by a 17.05% ROE and 7.10% FCF yield. The valuation is not cheap, but it remains below the average target and trades at a premium that reflects its execution record.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $10.29B
- P/E
- 26.48
- Fwd P/E
- 22.09
- PEG
- 1.31
- P/S
- 1.88
- P/B
- 4.13
- EV/EBITDA
- 19.09
- Div Yield
- 0.14%
- Gross Margin
- 14.73%
- Op Margin
- 8.97%
- Net Margin
- 7.03%
- ROE
- 16.63%
- ROIC
- 7.40%
Latest fiscal year · YoY change
- Revenue
- $5.06B+18.7%
- Gross Profit
- $799.45M+19.8%
- Op Income
- $425.31M
- Net Income
- $343.97M+15.4%
- EPS
- $6.00+14.1%
- OCF Growth
- +62.5%
- FCF Growth
- +96.2%
- 52W High
- $218.00
- 52W Low
- $141.58
- 50D MA
- $177.47
- 200D MA
- $182.25
- Beta
- 0.65
- RSI (14)
- 44
- Avg Volume
- 358.02K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Ensign delivered another strong quarter with 14.5% revenue growth, 23.9% GAAP EPS growth, and a raised full-year 2026 outlook, while continuing to lean into acquisitions and same-store occupancy gains.· October 28, 2026
- GAAP diluted EPS was $1.76, up 23.9%; adjusted diluted EPS was $2.03, up 23.8%.
- Consolidated GAAP and adjusted revenue were both $1.48 billion, up 14.5% year over year; GAAP net income rose to $104.3 million.
- Same-store occupancy was 84.1% and transitioning occupancy was 86.1%; same-store skilled mix revenue rose 10.7% and skilled days rose 7.2%.
- Management raised 2026 EPS guidance to $7.94-$8.02 and lifted the low end of revenue guidance to $5.89 billion while keeping the high end at $5.92 billion.
- The company added 22 new operations during and since the quarter, including entry into Florida, Colorado, Washington, and Texas, but said many of these are turnaround assets that will take time to contribute.
Reported Q3 results included GAAP diluted EPS of $1.76, up 23.9%, and adjusted diluted EPS of $2.03, up 23.8%. Consolidated GAAP revenue and adjusted revenue were both $1.48 billion, up 14.5% year over year; GAAP net income was $104.3 million, up 24.4%, and adjusted net income was $120.5 million, up 24.9%. Cash and cash equivalents were $337.6 million, cash flow from operations was $512.3 million, and lease-adjusted net debt to EBITDAR was approximately 2.0x. For 2026, management raised EPS guidance to $7.94-$8.02 per diluted share and raised the low end of revenue guidance to $5.89 billion while maintaining the high end at $5.92 billion; guidance assumes about 59.5 million weighted average shares and a 25.0% tax rate.
Barry Port struck a highly upbeat tone, calling the quarter “another outstanding quarter” and emphasizing that Ensign’s mission, culture, and 1 CLINICAL model are the foundation of both clinical and financial performance. He highlighted strong quality metrics, occupancy momentum, better payer mix, and the idea that patients and referral sources are choosing Ensign because of outcomes. He also stressed that the company still has meaningful organic runway at 84.0% occupancy and is confident in both 2026 and 2027, supported by ongoing acquisitions and operational execution.
Suzanne Snapper focused on the numbers, noting strong year-over-year growth in EPS, revenue, and net income, plus solid liquidity and leverage. She cited $337.6 million of cash, $512.3 million of cash flow from operations, more than $730 million of available line-of-credit capacity, and more than $1 billion of dry powder when combined with cash. She also pointed to a quarterly dividend of $0.065 per share and said the 2026 guidance reflects acquisitions expected through Q4, reimbursement assumptions, and continued occupancy and skilled-mix strength.
Analysts pressed management on Florida, asking about regulatory, labor, payer, and litigation risks; Barry said the litigation environment is a meaningful deterrent but that rates are now more stable, labor is good, regulation is middle of the road, and a seasoned leader has already been laying groundwork locally. On the recent acquisitions, management said they are turnaround-heavy, clinically and physically challenged, and likely to take a year or more to become meaningful contributors. Questions on elevated skilled mix and M&A pace drew the response that stronger outcomes are driving trust across payers, while deal flow remains broad-based and management is comfortable growing at 50 to 60 acquisitions a year, though it will stay selective.
The call showed clear operating momentum: higher occupancy, stronger skilled mix, and growth across all payer categories, alongside industry-leading quality and staffing metrics. Management also believes the balance sheet and acquisition pipeline support continued expansion, with several new deals already lining up for next year.
Management repeatedly said many of the newer acquisitions, including the Florida entry, are turnaround assets that are clinically, operationally, and physically challenged and will take time to contribute. Risks called out include Florida’s litigation environment, reimbursement and state-budget variability, seasonality, staffing, and the possibility that recent deals may take a year or more to become accretive.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 96.4%
- Shares Outstanding
- 58.34M
- Float Shares
- 56.24M
of shares held by institutions
562 13F filers
Buy/sell ratio 4.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 6.06M | ▼ 15.15K |
| Blackrock, Inc. | 5.85M | ▼ 1.52M |
| Baillie Gifford & Co | 4.67M | ▼ 361.35K |
| Vanguard Portfolio Management LLC | 2.87M | ▼ 253.74K |
| Fmr LLC | 2.70M | ▲ 158.16K |
| Vanguard Capital Management LLC | 2.62M | ▲ 31.71K |
| Capital Research Global Investors | 2.33M | ▲ 310.88K |
| Wasatch Advisors LP | 2.04M | ▼ 239.93K |
| State Street Corp | 1.82M | ▲ 22.40K |
| Geode Capital Management, LLC | 1.50M | ▼ 169.51K |
| Arrowstreet Capital, Limited Partnership | 1.08M | ▲ 617.43K |
| Dimensional Fund Advisors LP | 987.19K | ▲ 23.36K |
Held by 511 ETFs
Biggest fund positions in ENSG by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 6, 26 | Keetch Chad | other | 387 |
| Nov 6, 26 | Burton Spencer | other | 351 |
| Nov 6, 26 | Port Barry | other | 550 |
| Nov 6, 26 | Snapper Suzanne D. | other | 489 |
| Nov 6, 26 | Uychiat Pison Marivic | other | 102 |
| Nov 4, 26 | Uychiat Pison Marivic | other | 1,600 |
| Nov 5, 26 | Uychiat Pison Marivic | other | 163 |
| Nov 4, 26 | Uychiat Pison Marivic | other | 4,000 |
| Oct 15, 26 | Parkinson Mark Vincent | other | 600 |
| Oct 16, 26 | Parkinson Mark Vincent | sell | 100 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ENSG coverage
Recent articles, reports, and earnings notes.

The Ensign Group (ENSG): Growth, Quality, and Premium Valuation
Ensign combines strong revenue and EPS growth with improving clinical outcomes and disciplined acquisitions. The stock looks attractive operationally, but its premium valuation and reimbursement mix keep the upside tied to continued execution.

Ensign’s short-report selloff is testing whether execution still beats the narrative
The short-report hit on Ensign is serious, but the selloff is running into a business that just posted record occupancy, 21.7% adjusted EPS growth, and higher full-year guidance. We see this as a test of whether allegations can overpower a long-running execution story, and right now execution still has the better numbers.

The Ensign Group (ENSG): Quality Growth at a Premium
Ensign is turning skilled nursing into a repeatable growth machine, with double-digit revenue and EPS growth, record occupancy, and a balance sheet that still supports acquisitions. The stock looks like a quality compounder, but valuation keeps the stance at Buy on pullbacks.
Want a deeper read on ENSG?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
The Ensign Group, Inc. Notice of December 7, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
prnewswire.com · Nov 20
ENSG DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages The Ensign Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ENSG
newsfilecorp.com · Nov 20
Canada's Ensign plans to grow drilling rig fleet in Venezuela
reuters.com · Nov 20
Kaplan Fox Notifies The Ensign Group, Inc. (NASDAQ: ENSG) Investors of an Upcoming Lead Plaintiff Deadline on December 7, 2026
globenewswire.com · Nov 20
Bronstein, Gewirtz & Grossman LLC Urges The Ensign Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
newsfilecorp.com · Nov 20
ENSG Investors: BFA Law Notifies Ensign Group Investors with Losses of the Filed Securities Fraud Class Action and Upcoming December 7 Court Deadline
globenewswire.com · Nov 20
Kaplan Fox Announces the Lead Plaintiff Deadline of December 7, 2026 in the Securities Class Action Against The Ensign Group, Inc. (ENSG)
newsfilecorp.com · Nov 20
ENSG FINAL DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages The Ensign Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ENSG
newsfilecorp.com · Nov 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 19, 2026 · Live quote · Not investment advice